Shares of Moderna Inc. (MRNA) rallied 1.9% in premarket trading Tuesday, after the biotechnology company said Gavi, the Vaccine Alliance, has exercised its option to buy an additional 176.5 million COVID-19 vaccine doses for the Covax program. Of the additional doses, 116.5 million doses are expected to be delivered in the first quarter of 2022, while 60 million doses are expected to be delivered in the second quarter of 2022. Covax still has the option to buy an additional 116.5 million COVID-19 vaccine doses for delivery in the third quarter of 2022, and an additional 116.5 million doses in the fourth quarter. Moderna's stock has soared 192.1% year to date through Monday, while the S&P 500 has gained 16.1%.
(END) Dow Jones Newswires
October 12, 2021 09:17 ET (13:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.